NCT06736912 - This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

November 11, 2025

Conditions

Chronic Idiopathic Constipation

Interventions

DRUG

IN-114199 2.5mg or placebo

IN-114199 2.5mg or placebo (1 Tablet, QD)

DRUG

IN-114199 10mg or placebo

IN-114199 10mg or placebo (1 Tablet, QD)

DRUG

IN-114199 20mg or placebo

IN-114199 10mg or placebo (2 Tablets, QD)

DRUG

IN-114199 40mg or placebo

IN-114199 10mg or placebo (4 Tablets, QD)

DRUG

IN-114199 5mg or placebo

IN-114199 2.5mg or placebo (2 Tablets, QD)

Trial Locations (1)

Seoul National University Hospital, Clinical Trial Center, Seoul